EF Hutton Acquisition Co. I upgraded shares of Carisma Therapeutics (NASDAQ:CARM – Free Report) to a strong-buy rating in a report released on Wednesday, Zacks.com reports.
Carisma Therapeutics Price Performance
NASDAQ CARM opened at $1.00 on Wednesday. Carisma Therapeutics has a twelve month low of $0.80 and a twelve month high of $3.42. The company has a debt-to-equity ratio of 1.39, a quick ratio of 3.25 and a current ratio of 3.25. The stock has a market capitalization of $41.54 million, a PE ratio of -0.56 and a beta of 1.49. The stock has a 50-day simple moving average of $1.00 and a 200 day simple moving average of $1.18.
Carisma Therapeutics (NASDAQ:CARM – Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.27) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.09. Carisma Therapeutics had a negative return on equity of 344.89% and a negative net margin of 350.08%. The business had revenue of $9.20 million during the quarter, compared to analysts’ expectations of $3.65 million. Research analysts anticipate that Carisma Therapeutics will post -1.43 EPS for the current year.
Hedge Funds Weigh In On Carisma Therapeutics
Carisma Therapeutics Company Profile
Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.
Read More
- Five stocks we like better than Carisma Therapeutics
- Health Care Stocks Explained: Why You Might Want to Invest
- Energy Vault Soars 100%: CEO Shares Why in MarketBeat Exclusive
- What is the Australian Securities Exchange (ASX)
- Meta’s Q3 Earnings Beat—Is This Dip a Golden Entry Opportunity?
- Where to Find Earnings Call Transcripts
- Top Nuclear Stocks Thriving on Soaring Energy Demand
Receive News & Ratings for Carisma Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Carisma Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.